Rankings
▼
Calendar
ZBIO
Zenas BioPharma, Inc.
$1B
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
-90.0% YoY
Gross Profit
-$134M
-2682.8% margin
Operating Income
-$164M
-3277.8% margin
Net Income
-$157M
-3139.8% margin
EPS (Diluted)
$-3.76
Cash Flow
Operating Cash Flow
-$120M
Free Cash Flow
-$120M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$370M
Total Liabilities
$58M
Stockholders' Equity
$312M
Cash & Equivalents
$320M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$50M
-90.0%
Gross Profit
-$134M
$50M
-368.3%
Operating Income
-$164M
-$37M
-341.2%
Net Income
-$157M
-$37M
-322.9%
← Q4 2023
All Quarters
Q1 2024 →
ZBIO FY 2024 Earnings — Zenas BioPharma, Inc. Revenue & Financial Results | Market Cap Arena